Belviq

/Belviq

Class action lawsuit alleges Eisai, Arena hid cancer risk of Belviq weight loss drug

Eisai Inc. and Arena Pharmaceuticals — the manufacturers of the drugs Belviq and Belviq XR (lorcaserin) — are facing a class action lawsuit alleging that the weight loss drugs increase the cancer risk of patients who used them. The lawsuits, filed in March at the U.S. District Court in White Plains, New York, is seeking class action status on behalf of patients who used Belviq for weight loss and were diagnosed with cancer. (more…)

By | 2020-04-28T18:33:21+00:00 April 28th, 2020|Belviq|Comments Off on Class action lawsuit alleges Eisai, Arena hid cancer risk of Belviq weight loss drug

FDA orders recall of Belviq weight loss drug after study finds increased cancer risk

The U.S. Food and Drug Administration has requested that Eisai Inc., the manufacturer of the weight loss drug Belviq, recall the drug after a study found that it could increase the risk of developing pancreatic cancer, colorectal cancer, or lung cancer. (more…)

By | 2020-04-27T17:24:41+00:00 April 27th, 2020|Belviq|Comments Off on FDA orders recall of Belviq weight loss drug after study finds increased cancer risk